Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 6Polycystic Ovary Syndrome 4Obesity 4Neoplasms 3Motor Activity 3Ovarian Diseases 2Ovarian Cysts 2Hereditary Breast and Ovarian Cancer Syndrome 2Cardiovascular Diseases 2Thyroid Neoplasms 1Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Primary Myelofibrosis 1Polycythemia Vera 1Overweight 1Myocardial Infarction 1Myeloproliferative Disorders 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Monoclonal Gammopathy of Undetermined Significance 1Metabolic Syndrome 1Intermittent Fasting 1Inflammation 1Growth Hormone-Secreting Pituitary Adenoma 1Fibrosis 1Feeding Behavior 1Diabetes Mellitus 1Cognitive Dysfunction 1Carcinoma, Hepatocellular 1Angina, Unstable 1

Interventions

Cyclophosphamide 62fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Busulfan 40ruxolitinib 39Mycophenolic Acid 36Whole-Body Irradiation 32Antilymphocyte Serum 29Methotrexate 27Cyclosporine 27fludarabine 24Melphalan 19Filgrastim 19Radiotherapy 15Methylprednisolone 13thymoglobulin 12Etoposide 12Cord Blood Stem Cell Transplantation 12Azacitidine 12Stem Cell Transplantation 11Sirolimus 1111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 10Decitabine 9Specimen Handling 8Prednisone 8Cytarabine 8Imatinib Mesylate 7Granulocyte Colony-Stimulating Factor 7Flow Cytometry 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Primary Myelofibrosis × Diet, Mediterranean × Clear all
NCT03907436 2020-03-24

NUTRIENT

University of California, Irvine

Phase NA Completed
30 enrolled
Myeloid

Inflammation, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡